Purigen Biosystems Signs Exclusive Distribution Agreement with Bonsai Lab to Strengthen its Commercial Presence in the European Union | Business

PLEASANTON, Calif.–(BUSINESS WIRE)–February 10, 2022–

Purigen Biosystems, Inc.a leading provider of next-generation technologies for the extraction and purification of nucleic acids from biological samples, today announced a new distribution agreement with Bonsai Lab. Under the terms of the agreement, Bonsai Lab has received exclusive rights to distribute, service and support Purigen’s Automated Ion Purification System ® and microfluidic kits in Portugal and Spain. Clinical and oncology researchers in these countries can now purchase and use the automated system, which has received a CE marking (European Conformity) in May 2021, to extract higher yields of purified DNA and RNA from challenging samples in one hour with minimal hands-on time.

This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220210005084/en/

Purigen Biosystems’ Ionic® Purification System enables researchers to extract higher yields of purified DNA and RNA from difficult samples in one hour with minimal hands-on time. (Photo: BusinessWire)

“Bonsai Lab is proud to bring innovative genomic technologies from around the world to our customers in Spain and Portugal,” said Rafael Calderón, General Manager of Bonsai Lab. “Purigen’s best-in-class purification tools will enable our customers to simplify their sample preparation workflows and generate high yields of DNA or RNA from different types of biological samples for the sequencing of novel generation, qPCR and other analytical protocols.”

Launched in the US market in 2019, the small benchtop ion purification system enables automated nucleic acid extraction with significantly increased yield and quality from a wide range of sample types, including cells cultured or sorted and formalin-fixed, paraffin-embedded (FFPE) tissue cells. Biological samples are gently lysed and then loaded into the Ionic ® Fluidics chip. The system then applies an electric field to the chip and the nucleic acids are isolated in their native form using the company’s basic isotachophoresis (ITP) technology. Since nucleic acids are not bound or stripped from fixed surfaces, nucleic acid loss and fragmentation is minimized while purification-induced bias is eliminated. The simplified workflow requires minimal hands-on time and ensures sufficient amounts of nucleic acid are available for all downstream analysis techniques, such as next-generation sequencing and qPCR. For more information, please visit www.purigenbio.com/products/ionic-system.

“Bonsai Lab is the leading provider of next-generation genomics technology in Spain and Portugal,” said Aziz Mustafa, PhD, Senior Director of European Sales and Business Development for Purigen Biosystems. “This agreement provides an excellent opportunity to expand our commercial activities in Europe and consolidate our position as a leading supplier of nucleic acid extraction and purification technologies.”

About Bonsai Lab

Bonsai Lab is a specialist distributor of innovative next-generation genomics solutions, operating in Spain and Portugal. By focusing on delivering high-quality solutions and providing top-notch customer support, Bonsai Lab represents “the perfect link between researchers and makers of the best analytical solutions”. For more information, visit www.bonsailab.com.

About Purigen Biosystems

Purigen Biosystems is redefining nucleic acid sample preparation with an innovative platform based on highly efficient isotachophoresis technology invented by Juan Santiago, PhD, and his team at Stanford University. Purigen’s automated benchtop instrument and accompanying microfluidic chip purify nucleic acid samples from a wide variety of sources, including tiny or otherwise challenging cancer samples. The purified nucleic acids are then immediately compatible with a wide range of downstream detection methods, including next-generation sequencing, PCR, and other genomic assays. For more information, visit www.purigenbio.com.

Ionic is a registered trademark of Purigen Biosystems, Inc. All other trademarks are the property of their respective owners. All products described herein are intended FOR RESEARCH ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220210005084/en/

CONTACT: Purigen Biosystems

Andre Noble

415-722-2129

[email protected] Lab

Elvis Pérez Mba, Product Manager

+34 916 629 877

[email protected]

KEYWORD: CALIFORNIA SPAIN NORTH AMERICA UNITED STATES EUROPE PORTUGAL

INDUSTRY KEYWORD: RESEARCH TECHNOLOGY MEDICAL DEVICES GENETICS SOFTWARE BIOTECHNOLOGY HARDWARE HEALTH SCIENCE ONCOLOGY

SOURCE: Purigen Biosystems, Inc.

Copyright BusinessWire 2022.

PUBLISHED: 02/10/2022 08:03 AM/DISC: 02/10/2022 08:03 AM

http://www.businesswire.com/news/home/20220210005084/en

Copyright BusinessWire 2022.

Comments are closed.